FAM
NTLA icon

Fred Alger Management’s Intellia Therapeutics NTLA Stock Holding History

Fred Alger Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,790
Closed -$894K – 500
2025
Q3 		$894K Buy
+51,790
New +$638K ﹤0.01% 374
2022
Q1 		– Sell
-39,889
Closed -$4.72M – 541
2021
Q4 		$4.72M Buy
39,889
+5,710
+17% +$715K 0.01% 307
2021
Q3 		$4.58M Buy
34,179
+14,164
+71% +$2.14M 0.01% 292
2021
Q2 		$3.24M Sell
20,015
-858
-4% -$66.8K 0.01% 328
2021
Q1 		$1.68M Buy
20,873
+8,447
+68% +$567K ﹤0.01% 352
2020
Q4 		$676K Buy
+12,426
New +$451K ﹤0.01% 397

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fred Alger Management's NTLA Position: Q4 2025 in Review

Fred Alger Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 51,790 shares — an estimated $894K sold.

Fred Alger Management first reported a position in NTLA in Q4 2020 and held it in 6 quarters. The position peaked at $4.72M in Q4 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Fred Alger Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fred Alger Management sold 51,790 Intellia Therapeutics shares in Q4 2025, an estimated $894K.
  • Fred Alger Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 6 quarters.
  • Fred Alger Management's Intellia Therapeutics position peaked at $4.72M in Q4 2021.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Fred Alger Management's 13F filing for Q4 2025, filed 17 Feb 2026.